ຈາກປະເທດຣັດເຊຍດ້ວຍຄວາມຮັກຕໍ່ອາເມລິກາ: Sputnik V ດຽວນີ້ຢູ່ເມັກຊິໂກ

1. The Coronavirus Vaccine from Russia Sputnik is now approved to be used in Mexico
2. Sputnik is 91.6% effective
3. ວັກຊີນ Sputnik V ແມ່ນອີງໃສ່ເວທີທີ່ໄດ້ຮັບການພິສູດແລະໄດ້ຮັບການສຶກສາເປັນຢ່າງດີຈາກບັນດາວັກຊີນ adenoviral ຂອງມະນຸດ, ເຊິ່ງເປັນສາເຫດຂອງໄຂ້ຫວັດ ທຳ ມະດາແລະມີມາເປັນເວລາຫລາຍພັນປີແລ້ວ.

---

The price is only $10.00 a shot, and it protects 91.6% against COVID-19. These are statistics published by the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund).

Sputnik is a Russian made COVID-19 vaccine now approved by the Federal Commission for the Protection against Sanitary Risk of Mexico (COFEPRIS).

The vaccine was approved under the emergency use authorization procedure without additional clinical trials in the country. Mexicohas become the first country of North America to approve Sputnik V and the 17th country in the world.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, ກ່າວວ່າ: 

“We welcome the decision of regulatory authorities of Mexico to register Sputnik V vaccine and include it in the national portfolio of vaccines against coronavirus. Partnership between Russia and Mexicowill save many lives and protect the population by using one of the best vaccines in the world. High efficacy of Sputnik V was confirmed yesterday by data published in one of the most respected medical journals, The Lancet. "

Sputnik V has a number of key advantages:

• Efficacy of Sputnik V is 91.6% as confirmed by the data published in The Lancet, one of the world’s oldest and most respected medical journals; Sputnik V provides full protection against severe cases of COVID-19.
• ວັກຊີນ Sputnik V ແມ່ນອີງໃສ່ເວທີທີ່ໄດ້ຮັບການພິສູດແລະໄດ້ຮັບການສຶກສາເປັນຢ່າງດີຈາກບັນດາວັກຊີນ adenoviral ຂອງມະນຸດ, ເຊິ່ງເປັນສາເຫດຂອງໄຂ້ຫວັດ ທຳ ມະດາແລະມີມາເປັນເວລາຫລາຍພັນປີແລ້ວ.
• Sputnik V ໃຊ້ສອງວັກທີ່ແຕກຕ່າງກັນ ສຳ ລັບການສັກຢາທັງສອງຄັ້ງໃນໄລຍະການສັກຢາ, ໃຫ້ພູມຕ້ານທານແກ່ຍາວກວ່າວັກຊີນໂດຍໃຊ້ກົນໄກການຈັດສົ່ງດຽວກັນ ສຳ ລັບການສັກຢາທັງສອງຄັ້ງ.
• ຄວາມປອດໄພ, ປະສິດທິພາບແລະການຂາດຜົນກະທົບໃນໄລຍະຍາວຂອງການສັກຢາວັກຊີນ adenoviral ໄດ້ຖືກພິສູດໂດຍການສຶກສາທາງຄລີນິກຫຼາຍກ່ວາ 250 ໃນໄລຍະສອງທົດສະວັດ.
• ນັກພັດທະນາວັກຊີນ Sputnik V ກຳ ລັງເຮັດວຽກຮ່ວມກັບ AstraZeneca ໃນການທົດລອງຮ່ວມກັນເພື່ອຊ່ວຍປັບປຸງປະສິດທິຜົນຂອງຢາວັກຊີນ AstraZeneca.
• ບໍ່ມີອາການແພ້ທີ່ແຂງແຮງທີ່ເກີດຈາກ Sputnik V.
• ອຸນຫະພູມການເກັບຮັກສາຂອງ Sputnik V ທີ່ + 2 + 8 C ໝາຍ ຄວາມວ່າມັນສາມາດເກັບຮັກສາໄວ້ໃນຕູ້ເຢັນ ທຳ ມະດາໂດຍບໍ່ ຈຳ ເປັນຕ້ອງລົງທືນໃນໂຄງລ່າງລະບົບຕ່ອງໂສ້ເຢັນຕື່ມອີກ.
• ລາຄາຂອງ Sputnik V ແມ່ນຕໍ່າກ່ວາ 10 ໂດລາຕໍ່ການສັກຢາ, ເຮັດໃຫ້ມັນມີລາຄາບໍ່ແພງທົ່ວໂລກ.

Russian Direct Investment Fund (RDIF) is Russia’s sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB2 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at www.rdif.ru